Brian Wong, MD
Clinical Cardiac Electrophysiology · Brooklyn, NYNPI 1770718959
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,431 of the $30,014 with a category attached, or 64.7%. 18 manufacturers reported payments, led by Abbott at 32.6% of the total.
Across 396 payments — averaging $75.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Boston Scientific$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- Biotronik Inc.$2K
- Medtronic$1K
- Biosense Webster, Inc.$1K
- plus $4K from 12 others
Across 24 payments — averaging $2382.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$45K
- Boehringer Ingelheim$12K
What the payments were for
- Consulting fees$8003%
- Speaking & faculty fees$3,75012%
- Travel & lodging$5,85219%
- Food & beverage$19,43165%
- Education$1561%
- Entertainment$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 102 | $9,786 |
| Boston Scientific | 186 | $8,840 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $4,190 |
| Biotronik Inc. | 23 | $1,555 |
| Medtronic(2 entities) | 13 | $1,084 |
| Biosense Webster, Inc. | 15 | $1,025 |
| Bardy Diagnostics, Inc. | 10 | $889 |
| Kestra Medical Technology Services, Inc. | 8 | $776 |
| Cvrx, Inc. | 5 | $718 |
| Johnson & Johnson | 8 | $351 |
| Terumo Medical Corporation | 2 | $295 |
| Abiomed | 1 | $150 |
| Boehringer Ingelheim | 1 | $125 |
| Medicomp Inc | 1 | $58 |
| Novartis | 2 | $54 |
| Scpharmaceuticals Inc. | 1 | $49 |
| Irhythm Technologies, Inc. | 1 | $44 |
| Stereotaxis Inc | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$4,066
- LifeVest$3,750
- Accent Pacemaker$1,703
- GENERAL - THERAPIES$1,542
- Watchman$1,191
- Assurity Pacemaker$981
- EVERA MRI XT DR SURESCAN$744
- Carto 3$729
- Barostim Neo System$673
- Acticor 7 VR-T DX$661
- Carnation Ambulatory Monitor$570
- RESONATE EL ICD VR$503
- ADVISOR$502
- ASSURITY$468
- Assure WCD$433
- WATCHMAN Access System$258
- XARELTO$249
- RESONATE$249
- LUX-Dx Insertable Cardiac Monitor$217
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$192
How this compares
$30,014 in reported general payments places this provider in the 60th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 647 | $542,459 |
| XareltoRivaroxaban | 344 | $275,814 |
| EntrestoSacubitril/Valsartan | 179 | $183,242 |
| CamzyosMavacamten | 17 | $139,884 |
| MultaqDronedarone Hcl | 63 | $83,317 |
| FarxigaDapagliflozin Propanediol | 59 | $55,250 |
| JardianceEmpagliflozin | 32 | $36,235 |
| VerquvoVericiguat | 20 | $19,916 |
| CorlanorIvabradine Hcl | 25 | $17,245 |
| VascepaIcosapent Ethyl | 25 | $10,402 |
| Amiodarone Hcl | 234 | $9,142 |
| Metoprolol Succinate | 448 | $6,214 |
| Praluent PenAlirocumab | 12 | $5,967 |
| Flecainide Acetate | 92 | $2,570 |
| Atorvastatin Calcium | 225 | $2,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $351 | $275,814344 claims |
| NovartisEntresto | $54 | $183,242179 claims |
| Boehringer IngelheimJardiance | $125 | $36,23532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Brooklyn
- Felix YangBrooklyn$407K
- Adam BudzikowskiBrooklyn$259K
- Bharath ReddyBrooklyn$117K
- Gregory CunnBrooklyn$57K
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- James IpNew York$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.